Market Introduction
Europe comprises five prominent countries, namely Germany, France, UK, Italy, and Spain. The market also comprises the rest of the countries in Europe. Europe's virus-like particles market is witnessing stronger growth due to new product approvals by the authorized bodies. For example, the first licensed malaria VLP based vaccine namely, "Mosquirix," was approved by the European regulators. In addition, countries like the UK, Germany, France, Italy, and Spain are the key contributing countries driving the demand for virus-like particles products in Europe.
As per the World Health Organization (WHO) report, currently, every single country in Europe is facing a real threat of COVID-19. The pace of virus transmission across the 53 countries of the WHO European Region is a matter of concern. To control the transmission, countries of Europe are conducting vaccination roll-outs at various stages. In Europe, various COVID-19 vaccines are currently being developed and are in clinical trials, in the countries such as the UK, Germany, and Russia. Among them, there are three vaccines in the UK, three vaccines in Germany, and 2 in Russia. Among these vaccines, there is one inactivated vaccine, two protein subunits, three viral vector vaccines, and two nucleic acid vaccines. To combat the coronavirus in the European region, Europe as a whole has made consistent efforts to drive vaccine development. The Bruegel report states that, prior to the COVID-19 pandemic, the EU announced funding of almost US$500 Million for vaccine and vaccination research through the Horizon 2020 research program during 2014-2020. Additionally, to combat COVID-19, the EU has offered emergency funds to support research and development for diagnostics, therapeutics, and vaccines. Initially, US$10 Million subsequently increased to US$ 47.5 Million and was allotted for research projects for responding to the COVID-19 pandemic. Moreover, the European Institute of Technology Health opened in April 2020 was a call to EIT partners to send proposals for COVID-19 projects with robust implementation with funding of each project.
Market Overview and Dynamics
The virus-like particles market in Europe is expected to grow from US$ 1,302.03 million in 2021 to US$ 2,203.61 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028. Vaccines form one of the significant segments of the pharmaceuticals industry. They have an extensive application in the immunization of humans and animals against common infections. Companies operating in the pharmaceuticals and biopharmaceuticals markets continuously focus on product innovations and developments to sustain competition in the market. For instance, the market players have been significantly investing in the development of vaccines against COVID-19 and studies related to VLP. The active developments by life sciences companies, coupled with government support for the same, is contributing to the VLP market growth.
Key Market Segments
In terms of product type, the hepatitis segment accounted for the largest share of the Europe virus-like particles market in 2021. In terms of source, the yeast segment accounted for the largest share of the Europe virus-like particles market in 2021. In term of application, vaccines segment held a larger market share of the virus-like particles market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virus-like particles market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; and Dynavax Technologies among others.
Reasons to buy report
Europe Virus-like Particles Market Segmentation
Europe Virus-like Particles Market – By Product type
Europe Virus-like Particles Market – By Source
Europe Virus-like Particles Market – By Application
Europe Virus-like Particles Market – By Country
Europe Virus-like Particles Market – Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,302.03 Million |
| Market Size by 2028 | US$ 2,203.61 Million |
| CAGR (2021 - 2028) | 7.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe Virus-like Particles Market is valued at US$ 1,302.03 Million in 2021, it is projected to reach US$ 2,203.61 Million by 2028.
As per our report Europe Virus-like Particles Market, the market size is valued at US$ 1,302.03 Million in 2021, projecting it to reach US$ 2,203.61 Million by 2028. This translates to a CAGR of approximately 7.8% during the forecast period.
The Europe Virus-like Particles Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Virus-like Particles Market report:
The Europe Virus-like Particles Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Virus-like Particles Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Virus-like Particles Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe Virus-like Particles Market
